CGS 26303

Drug Profile

CGS 26303

Latest Information Update: 10 Feb 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antihypertensives; Phosphonic acids; Tetrazoles
  • Mechanism of Action Endopeptidase inhibitors; Endothelin-converting enzyme 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cerebral vasospasm; Heart failure; Hypertension

Most Recent Events

  • 10 Feb 2006 No development reported - Preclinical for Cerebral vasospasm in USA (unspecified route)
  • 10 Feb 2006 No development reported - Preclinical for Heart failure in France (unspecified route)
  • 04 Apr 2002 Preclinical trials in Heart failure in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top